Reyhaneh Hooshmandabbasi

Reyhaneh Hooshmandabbasi

Auto-generated profile, based on publicly available information

Reyhaneh Hooshmandabbasi

University of Zürich

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2019 in Journal of Morphology
Verified
Journal Article
Closed access
PDF file
AKAli Kazemian
Ali Kazemian
RHReyhaneh Hooshmandabbasi
Reyhaneh Hooshmandabbasi
ESElisabeth M. Schraner
Elisabeth M. Schraner
ABAlois Boos
Alois Boos
KKKarl Klisch
Karl Klisch

1 October 2022 in Journal of Ilam University of Medical Sciences
Verified
Journal Article
Open access
PDF file
ZTZahra Tootian
Zahra Tootian
SFSimin Fazelipour
Simin Fazelipour
MSMohammad Taghi Sheibani
Mohammad Taghi Sheibani
HEHossien Erik-Aghaji
Hossien Erik-Aghaji
RAReyhaneh Hooshmand Abbasi
Reyhaneh Hooshmand Abbasi
Introduction: Aspartame is one of the synthetic sweeteners widely used in the food industry as a sugar substitute in recent decades. The present study aimed to investigate the effect of different doses of aspartame on histological and histomorphometric changes in the stomach in BALB/C mice. Material & Methods: In this study, ...

14 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RHReyhaneh Hooshmandabbasi
Reyhaneh Hooshmandabbasi
AKAli Kazemian
Ali Kazemian
RSRahul Singha
Rahul Singha
MBManuel Vielma Blanco
Manuel Vielma Blanco
NBNiloufar Nikkhah Bahrami
Niloufar Nikkhah Bahrami
CMCaroline Maake
Caroline Maake
Introduction: Therapeutic ultrasound has been extensively studied in ablative and sonodynamic contexts, leaving the intrinsic bioactivity of continuous non-thermal low-intensity ultrasound (LIU) largely uncharacterized. Objectives: To characterize the tumor biological and immunomodulatory effects of non-thermal continuous LIU in complementary in vitro and in vivo breast cancer models, underpinned by a standardized exposure platform characterized through finite element simulations and experimental validation. Methods: Acoustic and thermal fields were characterized and optimized using in silico simulations and validated against hydrophone and temperature measurements to ensure homogeneous, non-thermal exposure (1MHz, 1W/cm 2 , 100% duty cycle). 4T07 murine mammary carcinoma spheroids received 20min LIU treatment, and metabolic activity, apoptosis, and intracellular stress-associated markers were assessed. In a syngeneic orthotopic 4T07 mammary carcinoma model in BALB/c mice, up to six LIU treatment cycles were administered; tumor growth, survival, histopathology, immunohistochemistry, bulk tumor RNA sequencing, spleen volume and plasma cytokine profiles were assessed. Results: In vitro and intratumoral temperatures remained within the physiological range (≤39°C) throughout exposure. In spheroids, LIU reduced ATP content by more than 40% and significantly increased apoptotic, Hsp70⁺ and Hsp90⁺ cell fractions. In vivo , cyclic LIU slowed tumor growth, increased intratumoral necrosis, and significantly prolonged time to humane endpoint compared to untreated controls. LIU promoted early intratumoral myeloid cell infiltration and shifted the tumor transcriptome (2,573 differentially expressed genes), with enrichment in gene sets associated with immunogenic cell death, pattern-recognition, inflammatory, and innate and adaptive immune programs and downregulation of pro-tumorigenic pathways. LIU enriched the transcriptional signatures of M1 macrophage polarization and, notably, B-cell compartment engagement, which has not previously been reported for standalone continuous mechanical ultrasound. LIU significantly attenuated tumor-associated splenomegaly and elevated plasma IL-1α, TNF-α, and IL-10. Conclusion: These results establish a reproducible preclinical platform and provide a hypothesis-generating mechanistic basis for evaluating LIU as an adjunct to immune checkpoint blockade. Abstract Figure:

19 September 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
JPJaclyn Parris
Jaclyn Parris
GWGiann Wiprächtiger
Giann Wiprächtiger
RHReyhaneh Hooshmandabbasi
Reyhaneh Hooshmandabbasi
CMCaroline Maake
Caroline Maake
Greta PatzkeGreta Patzke
Greta Patzke
Nanoparticles composed of selected polyoxometalates (POMs) and carboxymethyl chitosan (CMC) were prepared, characterized, and tested for anticancer activity to establish structure-activity relationships. Cell viability was investigated immediately after treatment and after 24 h to assess both cell recovery and delayed cytotoxicity. The study focused on three questions: (a) trends in cytotoxicity based on POM nuclearity and heteroatoms, (b) effects of CMC encapsulation strategies on cytotoxicity and cellular uptake, and (c) cell viability after a recovery period. Among polyoxotungstates, [NaP5W30O110]14-, with a high tungsten content, showed the greatest cytotoxicity towards PC-3 cells at low concentrations. [Co4(H2O)2(PW9O34)2]10- demonstrated moderate cytotoxicity with an IC50 of 437 ± 23 μM for MRC-5 cells, compared to 11 ± 0.3 μM for [NaP5W30O110]14-. Both POMs were encapsulated in a CMC matrix, forming nanoparticles of 100-250 nm, and analyzed by FT-IR and Raman spectroscopy, DLS, and cryo-TEM, and tested against MRC-5, PC-3, and HeLa cells. It was found that forming nanoparticles increased the magnitude of cytotoxicity compared to the free POM, especially for the lower end of the concentrations tested. However, ICP-MS analyses did not point to significant differences between the uptake of tungsten in cells treated with 250 μM [Co4(H2O)2(PW9O34)2]10- compared to the corresponding nanoparticle system. Furthermore, we newly monitored the cell viability after a 24 h rest period without treatment, allowing for observations of delayed negative or positive effects on the cells. This thorough approach revealed that the preparative strategy applied for encapsulation of [Co4(H2O)2(PW9O34)2]10- in CMC selectively influences the toxicity against HeLa and PC-3 cells compared to the normal MRC-5 cell line.